PPI plus aspirin improves outcomes in Barrett’s esophagus

The combination of aspirin and a high-dose proton-pump inhibitor (PPI) improves outcomes in patients with Barrett’s esophagus, according to results of the The Aspirin and Esomeprazole Chemoprevention in Barrett’s metaplasia Trial (AspECT)


Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *